Highlights Bavarian Nordic A/S

Equities

BAVA

DK0015998017

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:35 2024-04-26 am EDT			5-day change	1st Jan Change
148.8 ^DKK	+3.26%		+1.02%	-16.12%

Mar. 13	Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	MT
Mar. 13	Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults	Mar. 13	MT
Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland	Mar. 13	CI
Bavarian Nordic A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Bavarian Nordic A/S Announces Accelerated Assessment for the Upcoming Marketing Authorisation Application for CHIKV VLP	Feb. 23	CI
Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024	Feb. 21	CI
Bavarian Nordic Confirms FY23 Revenue Growth Outlook	Nov. 16	MT
Bavarian Nordic A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023	Nov. 16	CI
Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk	23-10-25	CI
Bavarian Nordic Receives EUR11 Million Smallpox Vaccine Contract	23-09-13	MT
Bavarian Nordic A/S Wins Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve	23-09-13	CI
Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2	23-08-31	CI
Bavarian Nordic A/S Raises Earnings Guidance for the Year 2023	23-08-07	CI
Bavarian Nordic A/S Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents	23-08-06	CI
Bavarian Nordic Wins $120 Million Contract for Bulk Production of Smallpox, Mpox Vaccines in US	23-08-03	MT
Bavarian Nordic A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-29	CI
Bavarian Nordic ends RSV vaccine programme after poor trial results	23-07-22	RE
Bavarian Nordic A/S Provides Update on RSV Vaccine Program	23-07-22	CI
Bavarian Nordic A/S Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate	23-06-27	CI
Bavarian Nordic Wins EUR10 Million Contract to Supply EU Reserve With Smallpox Vaccines	23-06-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bavarian Nordic A/S

Equities

BAVA

DK0015998017

Highlights

Filters